Company news

Arvinas, Inc. news in 2022

Arvinas, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)

November 21, 2022

Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 7, 2022

Arvinas to Present at Upcoming Conferences

October 31, 2022

Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award

October 26, 2022

Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

October 2, 2022

Arvinas Gives Back to Local Greater New Haven Community

September 29, 2022

Arvinas to Present at Bank of America Securities Precision Oncology Conference

September 25, 2022

Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations

August 14, 2022

Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 3, 2022

Arvinas Appoints John Northcott as Chief Commercial Officer

July 31, 2022

Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

June 1, 2022

Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations

May 31, 2022

GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration

May 8, 2022

Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 4, 2022

Arvinas to Present at Bank of America Securities 2022 Healthcare Conference

May 2, 2022

Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

February 27, 2022

Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer

February 16, 2022

Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting

February 13, 2022

Decks in 2022